Back to Search
Start Over
Clinical use of [18F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants.
- Source :
- Pituitary; Oct2024, Vol. 27 Issue 5, p614-624, 11p
- Publication Year :
- 2024
-
Abstract
- Purpose: To assess the utility of [<superscript>18</superscript>F]fluoroethyl-L-tyrosine PET co-registered with magnetic resonance imaging ([<superscript>18</superscript>F]FET-PET/MRI<superscript>CR</superscript>) in patients with difficult-to-localize prolactinoma to inform clinical decision-making and (surgical) treatment planning. Methods: Retrospective cohort study of 17 consecutive patients with prolactinoma undergoing [<superscript>18</superscript>F]FET-PET/MRI<superscript>CR</superscript> between October 2020 and September 2022 for either (1) additional information in case of difficult-to-visualize remnants after prior transsphenoidal surgery (TSS), or pharmacological treatment, or (2) radiological diagnosis in absence of a (clear) adenoma on diagnostic/post-treatment conventional MRI. Results: [<superscript>18</superscript>F]FET-PET/MRI<superscript>CR</superscript> identified a lesion in 14/17 patients, yet failed to identify active lesions in 2 patients with negative conventional MRI despite prolactin > 7.5 times upper limit of normal. [<superscript>18</superscript>F]FET-PET/MRI<superscript>CR</superscript> results were inconclusive in 1 patient due to diffuse tracer uptake 10 weeks post-surgery. [<superscript>18</superscript>F]FET-PET/MRI<superscript>CR</superscript> was completely concordant with a suspected lesion on conventional MRI in 10/17 patients, and partially concordant in 3/17 patients. New foci were identified in 4/17 patients. The [<superscript>18</superscript>F]FET-PET/MRI<superscript>CR</superscript> conclusions influenced clinical shared decision-making in 15/17 patients, of whom 7 patients underwent TSS and 8 refrained from TSS. One patient underwent TSS despite negative [<superscript>18</superscript>F]FET-PET/MRI<superscript>CR</superscript>, and one patient underwent additional imaging. Intraoperative findings corresponded with [<superscript>18</superscript>F]FET-PET/MRI<superscript>CR</superscript> in 5/8 patients, and immunohistochemistry was positive in 5/8 patients. The treatment goal was achieved in 7/8 patients, and remission was achieved in 5/7 patients in whom total resection was considered feasible. Conclusion: [<superscript>18</superscript>F]FET-PET/MRI<superscript>CR</superscript> can be of added value in the preoperative decision-making process for selected patients with difficult-to-localize prolactinoma (remnants), or patients lacking a substrate on conventional MRI. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1386341X
- Volume :
- 27
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Pituitary
- Publication Type :
- Academic Journal
- Accession number :
- 180518844
- Full Text :
- https://doi.org/10.1007/s11102-024-01430-y